Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Paris saponin VII promotes TRIP12-mediated SOD1 degradation to synergize with idarubicin in ROS-dependent acute myeloid leukemia cell death.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ni Runfeng, Ding Ning, Shi Yirong, Liu Milin, Wang Jing, Tao Yuchen, Bao Jizhang, Mao Yuanfei, Lu Jiahui
Аннотация
BACKGROUND: Acute myeloid leukemia (AML) cells evade apoptosis through antioxidant mechanisms. Paris saponin VII (PS VII), a steroidal saponin, exhibits antitumor activity in solid malignancies, but its role in AML remains unclear.
PURPOSE: This study investigated the antileukemic effects of PS VII on AML and the underlying mechanism, and evaluated its synergy with idarubicin (Ida).
METHODS: Using human SKM-1 and murine C1498 AML cell lines, we assessed antileukemic effects of PS VII in vitro. Subcutaneous and systemic leukemia mouse models were employed for in vivo validation. Mechanistic studies integrated DIA-based proteomics, co-immunoprecipitation, surface plasmon resonance, and ubiquitination assays to elucidate the molecular basis.
RESULTS: PS VII bound to superoxide dismutase 1 (SOD1) and promoted its proteasomal degradation. This process was mediated by TRIP12-dependent K48-linked polyubiquitination at lysine residues 10 and 37. SOD1 degradation elevated reactive oxygen species (ROS) levels and induced mitochondrial dysfunction. High SOD1 expression was associated with poor prognosis in AML patients. PS VII and Ida synergistically induced ROS-dependent apoptosis in vitro and in vivo.
CONCLUSION: PS VII functions as a natural compound SOD1 degrader that triggers ROS-dependent AML cell death through TRIP12-mediated ubiquitin-proteasomal degradation. Its synergy with Ida provides a potential combination strategy that increases cellular sensitivity to oxidative stress and cell death.
PURPOSE: This study investigated the antileukemic effects of PS VII on AML and the underlying mechanism, and evaluated its synergy with idarubicin (Ida).
METHODS: Using human SKM-1 and murine C1498 AML cell lines, we assessed antileukemic effects of PS VII in vitro. Subcutaneous and systemic leukemia mouse models were employed for in vivo validation. Mechanistic studies integrated DIA-based proteomics, co-immunoprecipitation, surface plasmon resonance, and ubiquitination assays to elucidate the molecular basis.
RESULTS: PS VII bound to superoxide dismutase 1 (SOD1) and promoted its proteasomal degradation. This process was mediated by TRIP12-dependent K48-linked polyubiquitination at lysine residues 10 and 37. SOD1 degradation elevated reactive oxygen species (ROS) levels and induced mitochondrial dysfunction. High SOD1 expression was associated with poor prognosis in AML patients. PS VII and Ida synergistically induced ROS-dependent apoptosis in vitro and in vivo.
CONCLUSION: PS VII functions as a natural compound SOD1 degrader that triggers ROS-dependent AML cell death through TRIP12-mediated ubiquitin-proteasomal degradation. Its synergy with Ida provides a potential combination strategy that increases cellular sensitivity to oxidative stress and cell death.